Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype
Giulio Metro(University of Perugia), Lucio Crinò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Rita Chiari(Azienda Ospedaliera di Perugia), Chiara Bennati(Azienda Ospedaliera di Perugia), Michele Giansanti(Azienda Ospedaliera di Perugia), Matthias Fischer(Goethe University Frankfurt), Vienna Ludovini(University of Perugia), Diana Giannarelli(Agostino Gemelli University Polyclinic), Luca Marcomigni(Azienda Ospedaliera di Perugia), Alice Baldi(Azienda Ospedaliera di Perugia), Annamaria Siggillino(Azienda Ospedaliera di Perugia), Vincenzo Minotti(Azienda Ospedaliera di Perugia), Simona Duranti(Ospedale Sacro Cuore Don Calabria)
Cited by 70
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240
The Effects of Different Ventilatory Settings on Pulmonary and Systemic Inflammatory Responses During Major Surgery
|Anesthesia & Analgesia|2004|233